Please note: The information displayed on this page might be outdated.
Forbius: Protein engineering platforms /design highly active & selective inhibitors of TGF-Beta and EGFR pathways for onco and fibrotic diseases. YM Bioscience spin-out (acquired by GILD). Ilia Tikhomirov, CEO, involved in devt of anti-EGFR agent and JAK inhibitor at YM. AVID100, anti-EGFR ADC in Ph 2a in EGFR IHC3+ cancer in triple (-) breast cancer, head & neck squamous cell carcinoma, and NSCLC. Ph 2a endpts incl ORR, PFS, PK, and safety. Ph 1 complete in all comers, good safety. AVID200, isoform selective TGF-Beta inhibitor in systemic sclerosis, myelofibrosis, scleroderma, and IO (+ in combo w checkpoint blockade). 3 Ph 1s to be started in parallel, open-label.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - West South Central
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Immuno-Oncology, Oncology
Listing
Private
Website:
Profiles:
Address:
101 W 6TH Street
Suite 501
Austin, TX 78701
United States

Company Participants at Solebury Trout CEO & Investor Ski Conference 2020

  • Ilia Tikhomirov, President and CEO
  • Julia Schoelermann, Business Development & Investor Relations

Lead Programs

AVID100 anti-EGFR ADC

Indication Phase
SCCHN 2
NSCLC 2
TNBC 2

AVID200 TGF-ß inhibitor

Indication Phase
Immune Oncology 1
Systemic Sclerosis 1
Myelofibrosis 1